This Biotech makes DNA Vaccines and Gene Therapy Possible in Lapland

14/10/2016 - 2 minutes

After Grenoble, we fly north to Finland to meet Santa’s reindeer and earn his good graces before Christmas. After a trip to the sauna and down time with Angry Birds, whose creator hails from the country, we moseyed over to visit FIT Biotech, our biotech of the week. 

fit-biotech-logo

City: Tampere, Finland

Founded: 1995

Employees: 12 + CEO

Financial Data: €12.5M Raised in August

Activities: Gene Transport Unit for DNA vaccines

Mission: FIT was established to develop an HIV vaccine, but in the process, the team developed its Gene Transfer Unit (GTU) that safely and efficiently transfers DNA to target cells. The technology can be used to make DNA-based vaccines and in gene therapies. Though FIT is still refining GTU, the company has now pivoted to focus on technology licensing through collaborations.

Comment: GTU hinges on E2, a transcriptional regulator derived from bovine papilloma virus (BPV).

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member